Announced Mon, 27 Jul · 15:52 IST
Senores Q1FY27 Investor Presentation: Strong Revenue Growth and Margin Expansion
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹1397.90
prior close
₹1408.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-6.5-6.1-7.4-5.3——————————
Up moveDown movePending
AI summary
Senores Pharmaceuticals reported Q1FY27 revenue of Rs 180.2 Cr, up 36% YoY. EBITDA grew 87% to Rs 53.8 Cr with margin expansion of 810 bps to 29.8%. PAT rose 56% to Rs 30.7 Cr, while gross margin improved 980 bps to 63.5%. Regulated Markets contributed 71% of revenue with 41.9% YoY growth and about 40% EBITDA margin. Pipeline includes 58 approved ANDAs with 187 strengths, 23 commercialized, and 39 molecules under development targeting USD 740 mn+ market.
Likely market impact
Strong Q1 with margin expansion of 810 bps and robust pipeline signal positive outlook. Unutilized IPO funds of Rs 100 Cr for Atlanta facility.